Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216879 | 0.91 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5215670 | 0.86 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5217927 | 0.85 | CRBN (0.43) | CRBNDDB1IKZF3TNF | |
| SCHEMBL5218003 | 0.83 | PDE3B (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL5162159 | 0.83 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5215745 | 0.81 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5215782 | 0.79 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL5217370 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3TNF | |
| SCHEMBL1398099 | 0.78 | CRBN (0.41) | CRBNDDB1ALDH1A1 | |
| SCHEMBL22720875 | 0.77 | CRBN (0.69) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456197-B1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | GRUENENTHAL GMBH (DE) | 2007-02-28 | — | — | EP | claimed |
| US-7183274-B2 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | claimed |
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| EP-1456197-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2004-09-15 | — | — | EP | claimed |
| WO-2003053956-A1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | Grünenthal GmbH (DE) | 2003-07-03 | — | — | WO | claimed |
| EP-1456197-B1 | PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 | GRUENENTHAL GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-7183274-B2 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | GRUENENTHAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020581-A1 | Piperidine-2,6-diones heterocyclically substituted in the 3-position | DPYD, CYP2D6, DHPS | CRBN 4553/4885DDB1 4687/4885IKZF3 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.